Advertisement

Topics

NantCell gets exclusive aldoxorubicin rights from CytRx

15:40 EDT 1 Aug 2017 | Elsevier Business Intelligence

CytRx Corp. grated NantCell LLC exclusive global rights to aldoxorubicin, a DNA topoisomerase inhibitor in late-stage trials ...

Original Article: NantCell gets exclusive aldoxorubicin rights from CytRx

NEXT ARTICLE

More From BioPortfolio on "NantCell gets exclusive aldoxorubicin rights from CytRx"

Quick Search
Advertisement
 

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...